Injection-free exenatide improves diabetes markers

10/3/2012 | Healio

Type 2 diabetes patients who received the injection-free exenatide ITCA 650 attained significant improvements in body weight, A1C, fasting plasma glucose and postprandial glucose levels, with greater effects seen in those who received higher doses than those who took a lower dose. However, researchers said 40 mcg and 60 mcg doses of ITCA 650 were better tolerated compared with the 80 mcg dose. The findings were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA